Hypertension and Histopathology Severity of Non-Alcoholic Fatty Liver Disease Among Adults with Obesity: A Cross-Sectional Study

References

• Arroyo-Johnson C, Mincey KD. Obesity epidemiology worldwide. Gastroenterol Clin North Am. 2016;45(4):571–579. doi:10.1016/j.gtc.2016.07.012
   PubMed Web of Science ®Google Scholar
• Instituto Nacional de Estadisticas e Informatica (INEI). Peru: Enfermedades No Transmisibles y Transmisibles, 2019 [Internet]; 2020. Available from: https://proyectos.inei.gob.pe/endes/2019/SALUD/ENFERMEDADES_ENDES_2019.pdf. Accessed August 8, 2023.
   Google Scholar
• Godoy-Matos AF, Silva Júnior WS, Valerio CM. NAFLD as a continuum: from obesity to metabolic syndrome and diabetes. Diabetol Metab Syndr. 2020;12(1):60. doi:10.1186/s13098-020-00570-y
   PubMed Web of Science ®Google Scholar
• Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease—Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64(1):73–84. doi:10.1002/hep.28431
   PubMed Web of Science ®Google Scholar
• Peng C, Stewart AG, Woodman OL, Ritchie RH, Qin CX. Non-alcoholic steatohepatitis: a review of its mechanism, models and medical treatments. Front Pharmacol. 2020;11:603926.
   PubMed Web of Science ®Google Scholar
• Armstrong MJ, Adams LA, Canbay A, Syn WK. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatol Baltim Md. 2014;59(3):1174–1197.
   PubMed Web of Science ®Google Scholar
• Velarde-Ruiz Velasco JA, García-Jiménez ES, García-Zermeño KR, et al. Extrahepatic complications of non-alcoholic fatty liver disease: its impact beyond the liver. Rev Gastroenterol Mex. 2019;84(4):472–481.
   Web of Science ®Google Scholar
• Veracruz N, Hameed B, Saab S, Wong RJ. The association between nonalcoholic fatty liver disease and risk of cardiovascular disease, stroke, and extrahepatic cancers. J Clin Exp Hepatol. 2021;11(1):45–81.
   PubMed Web of Science ®Google Scholar
• Cattazzo F, Lombardi R, Mantovani A, et al. Subclinical and clinical atherosclerosis in non-alcoholic fatty liver disease is associated with the presence of hypertension. Nutr Metab Cardiovasc Dis. 2022;32(12):2839–2847.
   PubMed Web of Science ®Google Scholar
• Ryoo JH, Ham WT, Choi JM, et al. Clinical significance of non-alcoholic fatty liver disease as a risk factor for prehypertension. J Korean Med Sci. 2014;29(7):973–979. doi:10.3346/jkms.2014.29.7.973
   PubMed Web of Science ®Google Scholar
• Ryoo JH, Suh YJ, Shin HC, Cho YK, Choi JM, Park SK. Clinical association between non-alcoholic fatty liver disease and the development of hypertension. J Gastroenterol Hepatol. 2014;29(11):1926–1931. doi:10.1111/jgh.12643
   PubMed Web of Science ®Google Scholar
• Roh JH, Park JH, Lee H, et al. A close relationship between non-alcoholic fatty liver disease marker and new-onset hypertension in healthy Korean adults. Korean Circ J. 2020;50(8):695–705. doi:10.4070/kcj.2019.0379
   PubMed Web of Science ®Google Scholar
• Kanwal F, Kramer JR, Li L, et al. Effect of metabolic traits on the risk of cirrhosis and hepatocellular cancer in nonalcoholic fatty liver disease. Hepatology. 2020;71(3):808–819. doi:10.1002/hep.31014
   PubMed Web of Science ®Google Scholar
• Alexander M, Loomis AK, van der Lei J, et al. Risks and clinical predictors of cirrhosis and hepatocellular carcinoma diagnoses in adults with diagnosed NAFLD: real-world study of 18 million patients in four European cohorts. BMC Med. 2019;17(1):95. doi:10.1186/s12916-019-1321-x
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Cuevas J, Santos A, Armendariz-Borunda J. Pathophysiological molecular mechanisms of obesity: a link between MAFLD and NASH with cardiovascular diseases. Int J Mol Sci. 2021;22(21):11629. doi:10.3390/ijms222111629
   PubMed Web of Science ®Google Scholar
• Di Sessa A, Umano GR, Miraglia Del Giudice E, Santoro N. From the liver to the heart: cardiac dysfunction in obese children with non-alcoholic fatty liver disease. World J Hepatol. 2017;9(2):69. doi:10.4254/wjh.v9.i2.69
   PubMedGoogle Scholar
• Nascimbeni F, Bedossa P, Fedchuk L, et al. Clinical validation of the FLIP algorithm and the SAF score in patients with non-alcoholic fatty liver disease. J Hepatol. 2020;72(5):828–838. doi:10.1016/j.jhep.2019.12.008
   PubMed Web of Science ®Google Scholar
• Alberti KGMM, Zimmet P, Shaw J. Metabolic syndrome--A new world-wide definition. A consensus statement from the International Diabetes Federation. Diabet Med J Br Diabet Assoc. 2006;23(5):469–480. doi:10.1111/j.1464-5491.2006.01858.x
   PubMed Web of Science ®Google Scholar
• Lonardo A, Nascimbeni F, Mantovani A, Targher G. Hypertension, diabetes, atherosclerosis and NASH: cause or consequence? J Hepatol. 2018;68(2):335–352. doi:10.1016/j.jhep.2017.09.021
   PubMed Web of Science ®Google Scholar
• Zhang Y, Zhang T, Zhang C, et al. Identification of reciprocal causality between non-alcoholic fatty liver disease and metabolic syndrome by a simplified Bayesian network in a Chinese population. BMJ Open. 2015;5(9):e008204. doi:10.1136/bmjopen-2015-008204
   PubMed Web of Science ®Google Scholar
• Dixon JB, Bhathal PS, O’Brien PE. Nonalcoholic fatty liver disease: predictors of nonalcoholic steatohepatitis and liver fibrosis in the severely obese. Gastroenterology. 2001;121(1):91–100. doi:10.1053/gast.2001.25540
   PubMed Web of Science ®Google Scholar
• Ciardullo S, Monti T, Sala I, Grassi G, Mancia G, Perseghin G. Nonalcoholic fatty liver disease and advanced fibrosis in US adults across blood pressure categories. Hypertension. 2020;76(2):562–568. doi:10.1161/HYPERTENSIONAHA.120.15220
   PubMed Web of Science ®Google Scholar
• Yuan Y, Naito H, Kitamori K, Hashimoto S, Asano T, Nakajima T. The antihypertensive agent hydralazine reduced extracellular matrix synthesis and liver fibrosis in nonalcoholic steatohepatitis exacerbated by hypertension. PLoS One. 2020;15(12):e0243846. doi:10.1371/journal.pone.0243846
   PubMed Web of Science ®Google Scholar
• Ikuta T, Kanno K, Arihiro K, et al. Spontaneously hypertensive rats develop pronounced hepatic steatosis induced by choline-deficient diet: evidence for hypertension as a potential enhancer in non-alcoholic steatohepatitis: hypertension enhances steatohepatitis. Hepatol Res. 2012;42(3):310–320. doi:10.1111/j.1872-034X.2011.00920.x
   PubMed Web of Science ®Google Scholar
• Alam S, Kabir J, Mustafa G, Gupta U, Hasan SKMN, Alam AKMK. Effect of telmisartan on histological activity and fibrosis of non-alcoholic steatohepatitis: a 1-year randomized control trial. Saudi J Gastroenterol. 2016;22(1):69. doi:10.4103/1319-3767.173762
   PubMed Web of Science ®Google Scholar
• Brookes MJ, Iqbal TH, Cooper BT. Hypertension and hepatic steatosis. Curr Hypertens Rep. 2008;10(3):182–187. doi:10.1007/s11906-008-0035-9
   PubMed Web of Science ®Google Scholar
• Oikonomou D, Georgiopoulos G, Katsi V, et al. Non-alcoholic fatty liver disease and hypertension: coprevalent or correlated? Eur J Gastroenterol Hepatol. 2018;30(9):979–985. doi:10.1097/MEG.0000000000001191
   PubMed Web of Science ®Google Scholar
• Sciacqua A, Perticone M, Miceli S, et al. Endothelial dysfunction and non-alcoholic liver steatosis in hypertensive patients. Nutr Metab Cardiovasc Dis. 2011;21(7):485–491. doi:10.1016/j.numecd.2009.11.015
   PubMed Web of Science ®Google Scholar
• European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO). EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease. J Hepatol. 2016;64(6):1388–1402. doi:10.1016/j.jhep.2015.11.004
   PubMed Web of Science ®Google Scholar